(Q33498535)

English

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 July 2017

Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study (English)

1 reference

Europe PubMed Central

27 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Veldhuis GJ

1

1 reference

Europe PubMed Central

27 July 2017

Willemse PH

2

1 reference

Europe PubMed Central

27 July 2017

Beijnen JH

3

1 reference

Europe PubMed Central

27 July 2017

Boonstra H

4

1 reference

Europe PubMed Central

27 July 2017

Piersma H

5

1 reference

Europe PubMed Central

27 July 2017

van der Graaf WT

6

1 reference

Europe PubMed Central

27 July 2017

de Vries EG

7

1 reference

Europe PubMed Central

27 July 2017

language of work or name

0 references

publication date

1 January 1997

1 reference

Europe PubMed Central

27 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

27 July 2017

75

1 reference

Europe PubMed Central

27 July 2017

703-709

1 reference

Europe PubMed Central

27 July 2017

5

1 reference

Europe PubMed Central

27 July 2017

https://scigraph.springernature.com/pub.10.1038/bjc.1997.125

0 references

Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Thrombosis with paclitaxel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Platinum-Taxol non-cross resistance in epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Effect of recombinant and purified human haematopoietic growth factors on in vitro colony formation by enriched populations of human megakaryocyte progenitor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Cisplatin neurotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Effects of interleukin-3 after chemotherapy for advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

14 July 2018

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

31 October 2018

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

31 October 2018

Stimulation of human hematopoietic progenitor cell proliferation and differentiation by recombinant human interleukin 3. Comparison and interactions with recombinant human granulocyte-macrophage and granulocyte colony-stimulating factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063352

31 October 2018

Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal growth of human megakaryocyte progenitors in serum-free cultures: effect of recombinant human interleukin 3

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant human G-CSF, GM-CSF, IL-3, and IL-1 alpha on the growth of purified human peripheral blood progenitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/9043028

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1997.125

1 reference

Europe PubMed Central

27 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

27 July 2017

1 reference

Europe PubMed Central

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33498535&oldid=1585845463"